---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-085543"
form_type: "8-K"
ticker: "ORKA"
cik: "0000907654"
company_name: "Oruka Therapeutics, Inc."
filed_at: "2024-10-04T23:59:59+00:00"
generated_at: "2026-05-30T21:03:59.592418+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Oruka Therapeutics amends CEO & SVP employment agreements, revising severance terms

## Summary
- CEO Klein: outside CIC, severance = 12 months base salary + 30% time-based equity vesting. Within CIC, 1.5x base+bonus + full equity acceleration.
- SVP Agarwal: outside CIC, 9 months base salary. Within CIC, 0.75x base+bonus + full equity acceleration and 9 months COBRA.
- Agreements also provide full time-based equity acceleration upon death/disability for Klein.
- Base salary ($600K for CEO) and target bonus (50% of base) remain unchanged.

## SEC filing metadata
- accession: 0001213900-24-085543
- form_type: 8-K
- ticker: ORKA
- cik: 0000907654
- company_name: Oruka Therapeutics, Inc.
- filed_at: 2024-10-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/907654/000121390024085543/0001213900-24-085543-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/907654/000121390024085543/ea0216746-8k_oruka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-085543
- JSON: https://secwatch.observer/filing/0001213900-24-085543.json
- Plain text: https://secwatch.observer/filing/0001213900-24-085543.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.